Cutera (NASDAQ:CUTR) had its price objective raised by Stephens from $18.00 to $24.00 in a report issued on Monday, The Fly reports. The firm currently has an overweight rating on the medical device company’s stock. The analysts noted that the move was a valuation call.

CUTR has been the topic of several other research reports. BidaskClub raised Cutera from a sell rating to a hold rating in a research report on Friday, June 5th. ValuEngine raised Cutera from a buy rating to a strong-buy rating in a research report on Tuesday, September 1st. Finally, Zacks Investment Research cut Cutera from a hold rating to a sell rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $27.50.

Shares of Cutera stock opened at $20.56 on Monday. The stock has a fifty day simple moving average of $15.91 and a 200 day simple moving average of $14.32. The company has a current ratio of 2.17, a quick ratio of 1.47 and a debt-to-equity ratio of 0.14. Cutera has a 12-month low of $9.07 and a 12-month high of $39.15. The company has a market capitalization of $361.73 million, a P/E ratio of -10.99 and a beta of 1.58.

Cutera (NASDAQ:CUTR) last posted its quarterly earnings data on Thursday, August 6th. The medical device company reported ($0.67) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.94) by $0.27. Cutera had a negative return on equity of 64.84% and a negative net margin of 18.22%. The business had revenue of $26.37 million for the quarter, compared to analysts’ expectations of $20.20 million. On average, analysts predict that Cutera will post -2.16 EPS for the current year.

In related news, Director J Daniel Plants acquired 11,540 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were bought at an average cost of $14.87 per share, for a total transaction of $171,599.80. Following the purchase, the director now owns 23,020 shares in the company, valued at approximately $342,307.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Katherine S. Zanotti acquired 3,085 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were bought at an average price of $16.36 per share, for a total transaction of $50,470.60. Following the completion of the purchase, the director now owns 20,178 shares in the company, valued at approximately $330,112.08. The disclosure for this purchase can be found here. Insiders have bought a total of 74,394 shares of company stock worth $1,112,629 in the last ninety days. Insiders own 2.30% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG raised its stake in shares of Cutera by 26.7% during the 1st quarter. Deutsche Bank AG now owns 288,172 shares of the medical device company’s stock valued at $3,764,000 after purchasing an additional 60,647 shares during the period. Wells Fargo & Company MN increased its stake in Cutera by 31.5% in the 1st quarter. Wells Fargo & Company MN now owns 76,542 shares of the medical device company’s stock worth $999,000 after acquiring an additional 18,339 shares during the last quarter. State Street Corp increased its stake in Cutera by 2.3% in the 1st quarter. State Street Corp now owns 530,797 shares of the medical device company’s stock worth $6,932,000 after acquiring an additional 11,755 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Cutera by 809.3% in the 1st quarter. JPMorgan Chase & Co. now owns 306,506 shares of the medical device company’s stock worth $4,003,000 after acquiring an additional 272,798 shares during the last quarter. Finally, Victory Capital Management Inc. increased its stake in Cutera by 33.8% in the 2nd quarter. Victory Capital Management Inc. now owns 1,527,960 shares of the medical device company’s stock worth $18,595,000 after acquiring an additional 385,695 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

Cutera Company Profile

Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.

Recommended Story: Fundamental Analysis and Choosing Stocks

The Fly

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.